PRO view: Treat to prevent recurrence of HCV

Liver International

Volumn 35, Issue 1, 2015, Pages 5-6

  Everson, Gregory T ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL THERAPY; CHOLESTATIC HEPATITIS; EDITORIAL; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C; HUMAN; ILEUS; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POSTOPERATIVE HEMORRHAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; RETRANSPLANTATION; SURGICAL INFECTION; VIRAL CLEARANCE; VIREMIA; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; HEPACIVIRUS; ORAL DRUG ADMINISTRATION; PROCEDURES; RECURRENT DISEASE;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; RECURRENCE;

EID: 84920992470     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12704     Document Type: Editorial

References (8)

1. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.
2. Flamm SL, Everson GT, Charlton M, et al. Ledipasvir/Sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective multicenter study. Hepatology 2014; 60: 320A.
3. Pellicelli AM, Montalbano M, Lionetti R, et al. Sofosbuvir and daclatasvir (24 Wks) for recurrent hepatitis c after liver transplantation: potent antiviral activity but lack of clinical benefit if treatment is given too late. Dig Liver Dis 2014; 46: 923-7.
4. Everson GT, Terrault NA, Lok AS, et al. Adult-to-Adult Living Donor Liver Transplantation Cohort Study. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57: 1752-62.
5. Afdhal N, Zeuzem S, Kwo P, et al. ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
6. Afdhal N, Reddy KR, Nelson DR, et al. ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.
7. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2014; DOI:10.1053/j.gastro.2014.09.023. [Epub ahead of print].
8. Terrault NA, Satapathy SK, Therapondos G, et al. Prevention of hepatitis C virus (HCV) recurrence with peri-transplant hepatitis C immune globulin combined with pre-transplant (Pre-LT) antiviral therapy (AVT). Hepatology 2014; 60: 206A.